| |  Online-Ressource |
|---|
| Verfasst von: | Hochhaus, Andreas [VerfasserIn]  |
|---|
| | Réa, Delphine [VerfasserIn] |
|---|
| | Boquimpani, Carla [VerfasserIn] |
|---|
| | Minami, Yosuke [VerfasserIn] |
|---|
| | Cortés, Jorge Eduardo [VerfasserIn] |
|---|
| | Hughes, Timothy P. [VerfasserIn] |
|---|
| | Apperley, Jane F. [VerfasserIn] |
|---|
| | Lomaia, Elza [VerfasserIn] |
|---|
| | Voloshin, Sergey [VerfasserIn] |
|---|
| | Turkina, Anna [VerfasserIn] |
|---|
| | Kim, Dong-Wook [VerfasserIn] |
|---|
| | Abdo, Andre [VerfasserIn] |
|---|
| | Fogliatto, Laura Maria [VerfasserIn] |
|---|
| | le Coutre, Philipp [VerfasserIn] |
|---|
| | Sasaki, Koji [VerfasserIn] |
|---|
| | Kim, Dennis Dong Hwan [VerfasserIn] |
|---|
| | Saußele, Susanne [VerfasserIn] |
|---|
| | Annunziata, Mario [VerfasserIn] |
|---|
| | Chaudhri, Naeem [VerfasserIn] |
|---|
| | Chee, Lynette [VerfasserIn] |
|---|
| | García-Gutiérrez, Valentin [VerfasserIn] |
|---|
| | Kapoor, Shruti [VerfasserIn] |
|---|
| | Allepuz, Alex [VerfasserIn] |
|---|
| | Quenet, Sara [VerfasserIn] |
|---|
| | Bédoucha, Véronique [VerfasserIn] |
|---|
| | Mauro, Michael J. [VerfasserIn] |
|---|
| Titel: | Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors |
|---|
| Titelzusatz: | longer-term follow-up of ASCEMBL |
|---|
| Verf.angabe: | Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha and Michael J. Mauro |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | March 2023 |
|---|
| Umfang: | 10 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Online veröffentlicht: 30. Januar 2023 ; Gesehen am 18.09.2024 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 37(2023), 3, Seite 617-626 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with ≥2 prior TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily. Consistent with previously published primary analysis results, after a median follow-up of 2.3 years, asciminib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib. The major molecular response (MMR) rate at week 96 (key secondary endpoint) was 37.6% with asciminib vs 15.8% with bosutinib; the MMR rate difference between the arms, after adjusting for baseline MCyR, was 21.7% (95% CI, 10.53-32.95; two-sided p = 0.001). Fewer grade ≥3 adverse events (AEs) (56.4% vs 68.4%) and AEs leading to treatment discontinuation (7.7% vs 26.3%) occurred with asciminib than with bosutinib. A higher proportion of patients on asciminib than bosutinib remained on treatment and continued to derive benefit over time, supporting asciminib as a standard of care for patients with CML-CP previously treated with ≥2 TKIs. |
|---|
| DOI: | doi:10.1038/s41375-023-01829-9 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1038/s41375-023-01829-9 |
|---|
| | kostenfrei: Volltext: https://www.nature.com/articles/s41375-023-01829-9 |
|---|
| | DOI: https://doi.org/10.1038/s41375-023-01829-9 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Chronic myeloid leukaemia |
|---|
| | Targeted therapies |
|---|
| K10plus-PPN: | 1902828623 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors / Hochhaus, Andreas [VerfasserIn]; March 2023 (Online-Ressource)
